Loading...
Market
How many new Alzheimer's treatments will be approved globally by end of 2025?
2
Eli Lilly•China•National Medical Products Administration•Eisai•Biogen•Leqembi•United States•Japan•United Kingdom•South Korea
Resolution / Starting Odds
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%
Global regulatory approval announcements and pharmaceutical industry reports
Story
Eli Lilly's Donanemab Approved in China for Early Alzheimer's Treatment, Following Eisai and Biogen's January Approval
Dec 18, 2024, 01:56 AM
Eli Lilly's Alzheimer’s treatment, donanemab, has received approval from China's National Medical Products Administration for use in patients with early symptomatic Alzheimer's disease. This approval offers a new option for patients in China following the earlier approval of Eisai and Biogen's Leqembi in January. Donanemab has previously been authorized in the United States, Japan, and the United Kingdom, expanding its availability for those affected by the disease. The approval comes as a joint research team from South Korea and the U.S. has revealed insights into the mechanism by which tau proteins, linked to Alzheimer's, are removed from the brain.
View original story
Similar markets
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
1-2 companies • 25%
3-4 companies • 25%
More than 4 companies • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
More than 3 competitors • 25%
2 to 3 competitors • 25%
1 competitor • 25%
No new competitors • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
None • 25%
1 to 2 • 25%
3 to 4 • 25%
More than 4 • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%